ASX ANNOUNCEMENT FDA FEEDBACK RECEIVED, REQUESTS ADDITIONAL RAT STUDY Key Points: • The US FDA has advised that the clinical hold on Argenica’s IND for xaranetide in acute ischaemic stroke remains in place, requesting an additional rat study. • The FDA has requested additional non-clinical...
FDA Feedback Received, Requests Additional Rat Study
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Argenica Therapeutics Ltd has received feedback from the FDA regarding its clinical hold on the IND for xaranetide in acute ischaemic stroke, which remains in place pending additional studies. The FDA has requested a non-clinical neurotoxicity study in rats to assess potential toxic effects before clinical dosing can commence in the US. Additionally, the FDA has revised the permitted clinical exposure limit, which the company disputes based on its own data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Becoming a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
- New Mechanism Findings Offer Insights Into Phase 2 Signal
- Notice of Annual General Meeting/Proxy Form
- Change of Director's Interest Notice
Later from Argenica Therapeutics
All Argenica Therapeutics news releasesFollow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics